Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals
The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...
Novavax: Navigating Fiscal Challenges and Strategic Shifts Amid COVID Vaccine Market Uncertainty
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
Novavax’s stock slides 7% as guidance cut offsets narrower-than-expected third-quarter loss
NovaVax Inc.’s stock NVAX tumbled 7% early Tuesday, after the company cut its full-year guidance, offsetting a narrower-than-expected third-quarter loss and better-than-expected revenue. The company ...
Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls
On Tuesday, Novavax Inc (NASDAQ:NVAX) reported third-quarter 2024 sales of $84.5 million, compared to $186.99 million a year, ...
Novavax Cuts FY24 Revenue View Below Market; Stock Drops In Pre-market - Update
Drug maker Novavax Inc. (NVAX), while reporting narrower net loss in its third quarter, on Tuesday trimmed its fiscal 2024 forecast ...
MarketWatch5h
Novavax Inc. stock underperforms Tuesday when compared to competitors
Shares of Novavax Inc. NVAX slid 6.10% to $8.46 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.09% to ...
Seeking Alpha11h
Novavax, Inc. (NVAX) Q3 2024 Earnings Call Transcript
Good morning and welcome to Novavax' Third Quarter 2024 Financial Results and Operational Highlights Conference Call. All participants will be in listen-only mode. [Operator Instructions] After ...
Wall Street muted as focus moves to economic data
Wall Street's main indexes were little changed on Tuesday following post-election gains over the past few days.
AOL13h
Novavax: Stock plunges after quarterly earnings, but sees hope in licensing deals
Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for ...
Business Insider17h
Novavax Resumes Phase 3 Vaccine Trials After FDA Hold
The latest update is out from Novavax ( (NVAX)). Novavax, a leader in vaccine development, announced the FDA’s removal of a clinical hold on their COVID-19-Influenza combination and influenza ...